CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · General Reference

SPV-400

pharmaceutical compound

Cross-disciplinary reference desk with index cards, atlas, dictionary and catalogue
General referenceInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionJun 10, 2026
Entity authorityQ140332752 ↗
Source-derived summary

SPV-400 is a tropomyosin receptor kinase B (TrkB) agonist which is under development for the treatment of neurological disorders. It is taken parenterally. The preclinical pharmacokinetics of SPV-400 have been studied and described. The drug is under development by Spave Science. As of August 2025, it is in the preclinical research stage of development for neurological disorders. The chemical structure of SPV-400 does not yet appear to have been disclosed.

Editorial summary

“SPV-400” enters the record as pharmaceutical compound. Crown Archives preserves that source wording while asking what SPV-400, pharmaceutical and compound can confirm, complicate or overturn.

Editorial reviewA dependable orientation record for establishing vocabulary, names and a first evidence trail. The current lead gives the account dated anchors—2025—that can be checked directly. The selected authority fields contribute no independent date. Its strongest next move is a source search built around SPV-400, pharmaceutical and compound.
Editorial analysis

Why this record matters

“SPV-400” is worth following because a concise public description often conceals a longer documentary argument. Here, SPV-400, pharmaceutical and compound provides the most credible route into that argument.

Evidence profile

Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated Jun 10, 2026. The linked authority identifier is Q140332752. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2025.

Critical limits

Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.

Best used for
  • Subject orientation
  • Search vocabulary
  • Locating named sources
Verify next

The closest primary source, responsible institution and strongest cited specialist reference.

Three-step research path

  1. Establish the record: confirm the title “SPV-400”, its source revision and the description used here.
  2. Expand the search: follow SPV-400 primary sources, SPV-400 archive and SPV-400 research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “SPV-400”?
  2. Which institution is responsible for the underlying evidence?
  3. What terminology or title could unlock a more precise catalogue search?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “SPV-400” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.